Sponsor Deadline
Posted: 5/13/2024

ML/AI Tools to Advance Genomic Translational Research (MAGen) - Development Sites (UG3/UH3 Clinical Trials Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications to explore the feasibility of developing Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease. NHGRI aims to establish a research Consortium, ML/AI Tools to Advance Genomic Translational Research (MAGen), to collaboratively identify both genomic and non-genomic factors influencing disease development in individuals carrying pathogenic genetic variants. The ML/AI tools will leverage existing multimodal genomic and non-genomic data and will be cross validated in genomic translational research settings to ensure the robustness and generalizability of the tools for translational purposes. In addition, the Consortium will explore the ethical, legal, and social implications (ELSI) of integrating ML/AI tools into genomic medicine through the establishment of an ELSI Framework for their development, and through implementation of ELSI research projects.

Funded MAGen Sites will work collaboratively with each other and the MAGen CC (RFA-HG-23-005) within the Consortium to meet the goals of this RFA. Therefore, applicants should read the MAGen CC NOFO (RFA-HG-23-005) to understand the role and expectation of the MAGen CC.


  • Letter of Intent Due Date(s): June 26, 2024
  • Application Due Date: July 26, 2024

RFA-HG-24-004 Expiration Date July 29, 2024

Amount Description

Awards are limited to $1.6 million per year total cost for five years.

The project period for this NOFO is 5 years (FY2025-FY2029).

Funding Type